423 related articles for article (PubMed ID: 28643145)
1. The prognostic value of volume-based parameters using
Park JS; Lee N; Beom SH; Kim HS; Lee CK; Rha SY; Chung HC; Yun M; Cho A; Jung M
Gastric Cancer; 2018 Mar; 21(2):213-224. PubMed ID: 28643145
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
3. Harmonized pretreatment quantitative volume-based
Kitajima K; Miyoshi Y; Sekine T; Takei H; Ito K; Suto A; Kaida H; Daisaki H; Yamakado K
Hell J Nucl Med; 2020; 23(3):272-289. PubMed ID: 33367302
[TBL] [Abstract][Full Text] [Related]
4.
Mi L; Zhao Y; Zhao X; Yin F; Yin X; Li N; Shi J; Han X; Duan X; Zhao M; Han G; Wang J
Cancer Biother Radiopharm; 2021 Oct; 36(8):662-671. PubMed ID: 32783634
[No Abstract] [Full Text] [Related]
5. Volumetric parameters on
Liu G; Hu Y; Cheng X; Wang Y; Gu Y; Liu T; Shi H
BMC Cancer; 2019 Aug; 19(1):790. PubMed ID: 31395059
[TBL] [Abstract][Full Text] [Related]
6.
Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C
Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031
[TBL] [Abstract][Full Text] [Related]
7. Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment?
Evangelista L; Cervino AR; Ghiotto C; Saibene T; Michieletto S; Fernando B; Orvieto E; Guarneri V; Conte P
Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1648-1655. PubMed ID: 26025244
[TBL] [Abstract][Full Text] [Related]
8. Whole-Body Metabolic Tumor Volume, as Determined by (18)F-FDG PET/CT, as a Prognostic Factor of Outcome for Patients With Breast Cancer Who Have Distant Metastasis.
Son SH; Lee SW; Jeong SY; Song BI; Chae YS; Ahn BC; Lee J
AJR Am J Roentgenol; 2015 Oct; 205(4):878-85. PubMed ID: 26204115
[TBL] [Abstract][Full Text] [Related]
9. Intra-tumor metabolic heterogeneity of gastric cancer on
Liu G; Yin H; Cheng X; Wang Y; Hu Y; Liu T; Shi H
Clin Exp Med; 2021 Feb; 21(1):129-138. PubMed ID: 32880779
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma.
Lim SM; Kim H; Kang B; Kim HS; Rha SY; Noh SH; Hyung WJ; Cheong JH; Kim HI; Chung HC; Yun M; Cho A; Jung M
Ann Nucl Med; 2016 May; 30(4):279-86. PubMed ID: 26837515
[TBL] [Abstract][Full Text] [Related]
11. The Volume-metabolic Combined Parameters from (18)F-FDG PET/CT May Help Predict the Outcomes of Cervical Carcinoma.
Sun Y; Lu P; Yu L
Acad Radiol; 2016 May; 23(5):605-10. PubMed ID: 26853968
[TBL] [Abstract][Full Text] [Related]
12. The prognostic role of FDG PET/CT before combined radio-chemotherapy in anal cancer patients.
Leccisotti L; Manfrida S; Barone R; Ripani D; Tagliaferri L; Masiello V; Privitera V; Gambacorta MA; Rufini V; Valentini V; Giordano A
Ann Nucl Med; 2020 Jan; 34(1):65-73. PubMed ID: 31728763
[TBL] [Abstract][Full Text] [Related]
13. Metabolic tumor burden on postsurgical PET/CT predicts survival of patients with gastric cancer.
Sun G; Cheng C; Li X; Wang T; Yang J; Li D
Cancer Imaging; 2019 Mar; 19(1):18. PubMed ID: 30902116
[TBL] [Abstract][Full Text] [Related]
14. [Correlations of
Wang JL; Shi AQ; Fan CC; Wang YZ; Guo GR; Liu JY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2022 Aug; 44(4):628-635. PubMed ID: 36065696
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
Ding CY; Guo Z; Sun J; Yang WP; Li TR
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
[No Abstract] [Full Text] [Related]
16. Predictive and prognostic potential of volume-based metabolic variables obtained by a baseline
Garcia-Vicente AM; Pérez-Beteta J; Amo-Salas M; Molina D; Jimenez-Londoño GA; Soriano-Castrejón AM; Pena Pardo FJ; Martínez-González A
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):73-79. PubMed ID: 29102649
[TBL] [Abstract][Full Text] [Related]
17. Relationship Between 18F-FDG PET/CT Findings and HER2 Expression in Gastric Cancer.
Chen R; Zhou X; Liu J; Huang G
J Nucl Med; 2016 Jul; 57(7):1040-4. PubMed ID: 26966162
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
[TBL] [Abstract][Full Text] [Related]
19. Validation of Metabolically Active Tumor Volume and Total Lesion Glycolysis as 18F-FDG PET/CT–derived Prognostic Biomarkers in Chemorefractory Metastatic Colorectal Cancer.
Woff E; Hendlisz A; Ameye L; Garcia C; Kamoun T; Guiot T; Paesmans M; Flamen P
J Nucl Med; 2019 Feb; 60(2):178-184. PubMed ID: 29959212
[TBL] [Abstract][Full Text] [Related]
20. Volumetric PET parameters can predict overall survival in advanced lung adenocarcinoma.
Yanarateş A; Yazici B
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):3-8. PubMed ID: 31818695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]